Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neena Brizmohun

Neena Brizmohun writes and commissions news, features and analysis to meet the regulatory, business and market access information needs of the companies and regulatory agencies that operate in the pharmaceutical and medical device space worldwide.

Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.

A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Advertisement
Set Alert for Articles By Neena Brizmohun

Latest From Neena Brizmohun

EMA OKs Seven New Drugs But Delivers Another Blow To Emmaus

Seven new drugs have this week moved closer to gaining EU approval following positive recommendations from the European Medicines Agency, but Emmaus’ glutamine product has fared less well and the company is considering another route for getting the drug to sickle cell disease patients in Europe

Europe Drug Review

Vertex Among Four Hopefuls Seeking EMA's Elusive Speedy Review

Vertex’s triple combination regimen for cystic fibrosis and two Ebola vaccines from Janssen are among the latest potential new products being considered for accelerated assessment by the European Medicines Agency.

Scottish HTA OKs Kymriah For Lymphoma After Novartis Drops Price

Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Europe Drug Review

Danish Regulator Offering Free Advice On How to Comply With New EU Regulations

The Danish Medicines Agency is testing a new regulatory advice service that medical device SMEs and start-ups anywhere in the world can apply to use.

Denmark Regulation

Australia To Improve Compliance For Device Systems And Procedure Packs

The Therapeutic Goods Administration is seeking feedback on proposals affecting manufacturers of packages containing therapeutic goods, at least one of which is a medical device or IVD.

Australia Compliance
See All
Advertisement
UsernamePublicRestriction

Register